25th Nov 2015 13:07
25 November 2015
Issue of Equity
Clinigen Group plc (the "Company", AIM: CLIN) announces that it has made an application for the admission to trading on AIM of 4,598 ordinary shares of 0.1 pence each in the Company (the "New Ordinary Shares"), which have been issued to satisfy the exercise of share options and rank pari passu with the existing shares of the Company. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 1 December 2015.
At admission the issued share capital of the Company will consist of 114,558,328 ordinary shares, with no shares held in treasury. The total number of voting rights in the Company will therefore be 114,558,328. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.
-Ends-
Contact Details
Clinigen Group plc |
Tel: +44 (0) 1283 495010 |
Peter George, Group Chief Executive Officer Shaun Chilton, Group Deputy CEO |
|
Martin Abell, Group Chief Financial Officer |
|
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade/Freddie Barnfield (Nominated Adviser) James Black/Tom Ballard (Corporate Broking) |
|
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 |
James Steel/Jock Maxwell Macdonald |
|
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow | Email: [email protected] |
Notes to Editors
About Clinigen Group
Clinigen Group is a global pharmaceutical and services company with a unique combination of businesses dedicated to delivering the right drug to the right patient at the right time.
The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; through Clinigen Clinical Trial Services we manage the supply of commercial medicines for clinical trials, through Idis Managed Access we run early access programs for our own and other companies' portfolios, our Idis Global Access team works directly with healthcare providers to enable ethical compliant access to unlicensed medicines, and through Clinigen Specialty Pharmaceuticals, we market our own portfolio of niche commercial products.
Clinigen is the global leader in clinical trial services and ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need. In October 2015, Clinigen acquired Link Healthcare, further strengthening our international distribution network in the AAA region - Asia, Africa and Australasia.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L